Tests experimental bispecific antibody drugs in lupus nephritis
Tests two experimental drugs for kidney inflammation caused by lupus in adults.
Plain-language title generated from the registry record
Registry title: Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Key facts
- Where
- Madrid, Málaga, Pamplona, and Sevilla, SpainSee the 5 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT06975787, who can take part
Where in Spain
- Hospital General Universitario Gregorio MarañónMadrid, SpainNot yet recruiting
- Hospital Universitario 12 de OctubreMadrid, SpainNot yet recruiting
- Hospital Universitario Regional de MálagaMálaga, SpainNot yet recruiting
- Clínica Universidad de navarraPamplona, SpainNot yet recruiting
- University Hospital Virgen Del Rocio S.L.Sevilla, SpainNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Regeneron Pharmaceuticals
- Trial code
- NCT06975787EU 2024-518288-37-00
- Record updated
- 27 October 2026
- Original description
This study is researching a particular group of experimental drugs administered for a short period in the treatment of participants with Lupus Nephritis (LN).Read full original descriptionShow less
A Dose Escalation Study Investigating Bispecific Antibody Therapy in Patients With Lupus Nephritis
This study is researching a particular group of experimental drugs administered for a short period in the treatment of participants with Lupus Nephritis (LN).
The main aim of the current study is to see how safe and tolerable the study drugs are in a long-term follow-up.
This is a main study, called an umbrella study, which includes several independent smaller sub-studies. Each of these smaller main sub-studies tests different drugs at the same time, all aimed at treating LN.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Key General Inclusion Criteria:; Diagnosis of Systemic Lupus Erythematosus (SLE) and LN, as described in the protocol; Participant must have refractory or relapsed disease, as described in the protocol; Key General Exclusion Criteria:; History of or active severe or unstable lupus-associated neuropsychiatric disease that is likely to require acute or emergent medical treatment or hospitalization; Active overlap syndrome with mixed connective tissue disease or systemic sclerosis within 12 months prior to screening or during screening; Catastrophic or severe antiphospholipid syndrome within 12 months prior to screening or during screening; NOTE: Other protocol defined inclusion/exclusion criteria apply.